Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids (Omacor) for the Treatment of IgA Nephropathy

Trial Profile

Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids (Omacor) for the Treatment of IgA Nephropathy

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2014

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications IgA nephropathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Kuhnil Pharmaceutical Company
  • Most Recent Events

    • 05 Apr 2014 New trial record
    • 26 Sep 2012
    • 21 Oct 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top